The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease


Kratz C., Niemeyer C., Castleberry R., Cetin M., Bergstrasser E., Emanuel P., ...More

BLOOD, vol.106, no.6, pp.2183-2185, 2005 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 106 Issue: 6
  • Publication Date: 2005
  • Doi Number: 10.1182/blood-2005-02-0531
  • Title of Journal : BLOOD
  • Page Numbers: pp.2183-2185

Abstract

Germ line PTPN11 mutations cause 50% of cases of Noonan syndrome (NS). Somatic mutations in PTPN11 occur in 35% of patients with de novo, nonsyndromic juvenile myelomonocytic leukemia (JIMML). Myeloproliferative disorders (MPDs), either transient or more fulminant forms, can also occur in infants with NS (NS/MPD). We identified PTPN11 mutations in blood or bone marrow specimens from 77 newly reported patients with JMML (n = 69) or NS/MPD (n = 8). Together with previous reports, we compared the spectrum of PTPN11 mutations in 3 groups: (1) patients with JMML (n = 10); (2) patients with NS/MPD (n = 19); and (3) patients with NS (n = 243). Glu76 was the most commonly affected residue in JMML(n = 45), with the Glu76Lys alteration (n = 29) being most frequent. Eight of 19 patients with NS/ MPD carried the Thr73Ile substitution. These data suggest that there is a genotype/pheno type correlation in the spectrum of PTPN11 mutations found in patients with JMML, NS/ MPD, and NS. This supports the need to characterize the spectrum of hematologic abnormalities in individuals with NS and to better define the impact of the PTPN11 lesion on the disease course in patients with NS/ MPD and JMML.